Blog Posts

Updated Guideline on Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer – ASCO

ASCO/X

May 8, 2025, 10:41

Updated Guideline on Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer – ASCO

American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:

“We issued a guideline update on Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.

For men whose castration-sensitive prostate cancer was previously treated with systemic therapy, the type of that prior treatment will guide the selection of their next therapy for metastatic castration-resistant prostate cancer (mCRPC).

It’s recommended that androgen-deprivation therapy be continued without stopping for patients with mCRPC.

Read full article.”

Updated Guideline on Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer - ASCO

More posts featuring American Society of Clinical Oncology on OncoDaily.

American Society of Clinical Oncology androgen deprivation therapy ASCO cancer fight against cancer Global fight against cancer mCRPC metastatic castration-resistant prostate cancer OncoDaily Oncology prostate cancer systemic therapy

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding